BALTIMORE, Aug. 3, 2012 (GLOBE NEWSWIRE) -- Goldman Small Cap Research,
a stock market research firm focused on the small cap and micro cap
sectors, has issued research coverage of Immunovative, Inc.
(OTCBB:IMUN), the exclusive licensee of a novel portfolio of
immunotherapy drug products to treat cancer.

Immunovative, Inc. is the exclusive worldwide licensee of any product
commercialization covered under Israel-based Immunovative Therapies,
Ltd.'s (ITL) current issued and pending patent application portfolio.
ITL has demonstrated in Phase I/II clinical trials that its novel,
targeted immunotherapy technology that uses the body's own immune
system to treat metastatic breast cancer (MBC), was able to eliminate
the need for chemotherapy and the risk of other lethal toxicity through
other treatment methods.

In the Goldman Opportunity Research report on the Company, analyst Rob
Goldman outlines his investment thesis.

"In our view, the ITL technology is poised to revolutionize the way we
treat cancer. The Company's groundbreaking therapy has proven in
clinical trials to substantially increase survival rate in patients
stricken with MBC while eliminating lethal toxicity, versus the
toxicity that occurs in standard approaches to treatment. Future trials
could confirm previous trial results and result in fast-track status
with the FDA. Plus, the technology appears to have indications for a
number of other cancers which should prompt additional trials down the
road as well."

To view a summary of the report or download the report in its entirety,
please visit

www.goldmanresearch.com

About Goldman Small Cap Research: Led by former Piper Jaffray analyst
and mutual fund manager Rob Goldman, Goldman Small Cap Research
produces small cap and micro cap stock research reports, daily stock
market blogs, and popular investment newsletters. For more information,
visit www.goldmanresearch.com.

A Goldman Small Cap Research report is not intended as an offering,
recommendation, or a solicitation of an offer to buy or sell the
securities mentioned or discussed. Please read the report's full
disclosures and analyst background on our website before investing.
Neither Goldman Small Cap Research nor its parent is a registered
investment adviser or broker-dealer with FINRA or any other agency. To
download our research, view our disclosures, or for more information,
visit www.goldmanresearch.com.

About Immunovative, Inc.: Immunovative, Inc. (OTCBB:IMUN) On December
15, 2011, Immunovative, Inc. ("IMUN") signed an exclusive License
Agreement (the "License Agreement") with Immunovative Therapies, Ltd.
("ITL"). Under the terms of the License Agreement, IMUN has been
granted an exclusive, worldwide license to commercialize any products
covered under ITL's current issued and pending patent application
portfolio, as well as the rights to any future patent applications,
including improvements or modifications to the existing applications
and any corresponding improvements or new versions of the existing
products. For more information, visit the Company's website at
www.imun.com


CONTACT: Goldman Small Cap Research
         Rob Goldman, Analyst
         410-609-7100
         rob@goldmanresearch.com